Skip to main content

Interleukin Genetics, Isis Pharma Expand Drug Testing Collaboration

NEW YORK (GenomeWeb) – Interleukin Genetics today announced an expansion of a collaboration to include a Phase I clinical study for Isis Pharmaceuticals' novel therapeutic ISIS-APO(a)-LRx. 

Interleukin will provide its testing kits, prepare DNA, run genotypes, and provide data for SNP genotypes for the IL-1 and lipoprotein(a) SNPs for Isis' study evaluating ISIS-APO(a)-LRx in healthy volunteers with elevated levels of Lp(a), an independent risk factor for cardiovascular disease. The study is the second Isis clinical study to use Interleukin's genetic tests in a trial design, Interleukin said. 

In January, the firms announced a deal to incorporate Interleukin's genetic testing services for a Phase II clinical study evaluating ISIS-APO(a)Rx in patients with high levels of Lp(a). 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.